Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to ...

When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...

IgAN research, focusing on real-world patient experiences, reveals unmet needs in disease education, affordability, and care navigationEXTON, PA, April 08, 2025 (GLOBE NEWSWIRE) -- Spherix Global ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

The U.S. Food and Drug Administration (FDA) on Wednesday granted accelerated approval for Novartis AG’s (NYSE:NVS) Vanrafia ...

FABHALTA Indications FABHALTA is a prescription ... and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission.

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).

Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.

FABHALTA is a prescription medicine used to ... and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission.

IgAN is a progressive, rare kidney disease in which the immune system attacks the kidneys, often causing glomerular ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...